Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Monotherapy with the Capsid Assembly Modulator ALG-000184 Results in Rapid Viral Load Reduction and High Viral Suppression Rates in Untreated HBeAg-Negative Subjects with Chronic Hepatitis B Virus Infection

Friday, March 28, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The study on ALG-000184, a capsid assembly modulator, demonstrated significant efficacy in reducing viral load and achieving high suppression rates in untreated HBeAg-negative patients with chronic hepatitis B virus infection. This monotherapy approach shows potential as a viable treatment option for this patient population.
Price reaction · baseline $9.66 (2025-03-27 close) · hit after-hours · 2 other ALGS headline(s) in the window, move may be shared
day 0 close
-5.6%
day 1
-14.6%
day 3 · peak
-21.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rapid viral load reduction observed in subjects
  • High rates of viral suppression achieved
  • Monotherapy shows promise for chronic HBV treatment

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a capsid assembly modulator being studied for chronic hepatitis B.

What were the results of the study on ALG-000184?

The study showed rapid viral load reduction and high viral suppression rates.

Who were the subjects in the ALG-000184 study?

The study focused on untreated HBeAg-negative subjects with chronic HBV infection.

What is the significance of viral suppression in HBV treatment?

Viral suppression is crucial for managing chronic HBV and preventing liver damage.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 hepatitis B viral load reduction chronic HBV viral suppression
Last updated: Mar 28, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →